Do analysts rate NKGN or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, NKGN or BGM?

BGM Group has higher revenue and earnings than NKGen Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.68 N/A BGM Group $25.10M 1.25 -$1.44M N/A N/A

Is NKGN or BGM more profitable?

Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% BGM Group N/A N/A N/A

Does the media prefer NKGN or BGM?

In the previous week, NKGen Biotech had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for NKGen Biotech and 1 mentions for BGM Group. BGM Group's average media sentiment score of 0.75 beat NKGen Biotech's score of 0.00 indicating that BGM Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BGM Group 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer NKGN or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, NKGN or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NKGen Biotech N/A N/A -$82.94M -$1.68 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is NKGN or NNVC more profitable?

NKGen Biotech's return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% NanoViricides N/A -87.90% -78.69%

Does the media prefer NKGN or NNVC?

In the previous week, NKGen Biotech had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for NKGen Biotech and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.25 beat NKGen Biotech's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NanoViricides 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LSTA or NKGN?

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 350.45%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Lisata Therapeutics is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lisata Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is LSTA or NKGN more profitable?

NKGen Biotech's return on equity of 0.00% beat Lisata Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lisata Therapeutics N/A -103.54% -83.08% NKGen Biotech N/A N/A -479.36%

Do analysts rate DARE or NKGN?

Dare Bioscience currently has a consensus price target of $10.00, indicating a potential upside of 378.47%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is DARE or NKGN more profitable?

Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% NKGen Biotech N/A N/A -479.36%

Does the media favor DARE or NKGN?

In the previous week, NKGen Biotech had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for NKGen Biotech and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dare Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NKGen Biotech 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer NKGN or ATNM?

Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 409.68%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than NKGen Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NKGen Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Actinium Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is NKGN or ATNM more profitable?

NKGen Biotech's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets NKGen Biotech N/A N/A -479.36% Actinium Pharmaceuticals N/A -100.85% -47.89%

NKGen Biotech (NKGN) Competitors

$0.06 0.00 (0.00%)

As of 07/2/2026 02:44 PM Eastern

Compare

NKGN vs. BGM, NNVC, LSTA, DARE, and ATNM

Should you buy NKGen Biotech stock or one of its competitors? MarketBeat compares NKGen Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NKGen Biotech include BGM Group (BGM), NanoViricides (NNVC), Lisata Therapeutics (LSTA), Dare Bioscience (DARE), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "pharmaceutical products" industry.

How does NKGen Biotech compare to BGM Group?

NKGen Biotech (NYSE:NKGN) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, media sentiment, risk, profitability, dividends and earnings.

In the previous week, NKGen Biotech had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for NKGen Biotech and 1 mentions for BGM Group. BGM Group's average media sentiment score of 0.75 beat NKGen Biotech's score of 0.00 indicating that BGM Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NKGen Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BGM Group	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
BGM Group	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has higher revenue and earnings than NKGen Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
BGM Group	$25.10M	1.25	-$1.44M	N/A	N/A

NKGen Biotech has a beta of 0.65, suggesting that its share price is 35% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.78, suggesting that its share price is 78% more volatile than the broader market.

76.2% of NKGen Biotech shares are owned by institutional investors. 10.4% of NKGen Biotech shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

BGM Group beats NKGen Biotech on 7 of the 9 factors compared between the two stocks.

How does NKGen Biotech compare to NanoViricides?

NKGen Biotech (NYSE:NKGN) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

NKGen Biotech has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

NanoViricides is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, NKGen Biotech had 1 more articles in the media than NanoViricides. MarketBeat recorded 2 mentions for NKGen Biotech and 1 mentions for NanoViricides. NanoViricides' average media sentiment score of 0.25 beat NKGen Biotech's score of 0.00 indicating that NanoViricides is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NKGen Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NanoViricides	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NKGen Biotech's return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
NanoViricides	N/A	-87.90%	-78.69%

Summary

NanoViricides beats NKGen Biotech on 7 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to Lisata Therapeutics?

Lisata Therapeutics (NASDAQ:LSTA) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

8.9% of Lisata Therapeutics shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 9.6% of Lisata Therapeutics shares are held by company insiders. Comparatively, 10.4% of NKGen Biotech shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, NKGen Biotech had 2 more articles in the media than Lisata Therapeutics. MarketBeat recorded 2 mentions for NKGen Biotech and 0 mentions for Lisata Therapeutics. Lisata Therapeutics' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company	Overall Sentiment
Lisata Therapeutics	Neutral
NKGen Biotech	Neutral

Lisata Therapeutics has a beta of 0.79, meaning that its stock price is 21% less volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

NKGen Biotech's return on equity of 0.00% beat Lisata Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lisata Therapeutics	N/A	-103.54%	-83.08%
NKGen Biotech	N/A	N/A	-479.36%

Lisata Therapeutics has higher revenue and earnings than NKGen Biotech. Lisata Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lisata Therapeutics	$170K	178.45	-$16.59M	-$1.86	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

Lisata Therapeutics currently has a consensus price target of $15.00, indicating a potential upside of 350.45%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Lisata Therapeutics is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lisata Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Lisata Therapeutics and NKGen Biotech tied by winning 6 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to Dare Bioscience?

Dare Bioscience (NASDAQ:DARE) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

In the previous week, NKGen Biotech had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for NKGen Biotech and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dare Bioscience	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NKGen Biotech	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dare Bioscience has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

6.7% of Dare Bioscience shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Comparatively, 10.4% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dare Bioscience currently has a consensus price target of $10.00, indicating a potential upside of 378.47%. Given Dare Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Dare Bioscience is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dare Bioscience has higher revenue and earnings than NKGen Biotech. Dare Bioscience is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.16M	27.05	-$13.40M	-$0.95	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
NKGen Biotech	N/A	N/A	-479.36%

Summary

Dare Bioscience beats NKGen Biotech on 8 of the 12 factors compared between the two stocks.

How does NKGen Biotech compare to Actinium Pharmaceuticals?

NKGen Biotech (NYSE:NKGN) and Actinium Pharmaceuticals (NYSE:ATNM) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

Actinium Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 409.68%. Given Actinium Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Actinium Pharmaceuticals is more favorable than NKGen Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NKGen Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Actinium Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

NKGen Biotech has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Actinium Pharmaceuticals has a beta of -0.02, indicating that its share price is 102% less volatile than the broader market.

76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 27.5% of Actinium Pharmaceuticals shares are held by institutional investors. 10.4% of NKGen Biotech shares are held by company insiders. Comparatively, 0.6% of Actinium Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, NKGen Biotech had 2 more articles in the media than Actinium Pharmaceuticals. MarketBeat recorded 2 mentions for NKGen Biotech and 0 mentions for Actinium Pharmaceuticals. NKGen Biotech's average media sentiment score of 0.00 equaled Actinium Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
NKGen Biotech	Neutral
Actinium Pharmaceuticals	Neutral

NKGen Biotech's return on equity of 0.00% beat Actinium Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NKGen Biotech	N/A	N/A	-479.36%
Actinium Pharmaceuticals	N/A	-100.85%	-47.89%

Actinium Pharmaceuticals has higher revenue and earnings than NKGen Biotech. Actinium Pharmaceuticals is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A
Actinium Pharmaceuticals	$90K	341.99	-$48.82M	-$0.75	N/A

Summary

Actinium Pharmaceuticals beats NKGen Biotech on 7 of the 13 factors compared between the two stocks.

Get NKGen Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NKGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NKGN vs. The Competition

Export

Metric	NKGen Biotech	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$7.84M	$353.15M	$7.16B	$23.53B
Dividend Yield	N/A	N/A	2.66%	3.98%
P/E Ratio	-0.01	N/A	28.02	31.55
Price / Sales	N/A	228.84	540.37	21.06
Price / Cash	N/A	22.44	49.26	25.36
Price / Book	-0.02	4.86	10.96	4.81
Net Income	-$82.94M	-$141.03M	$3.57B	$1.07B
7 Day Performance	N/A	2.78%	2.12%	0.56%
1 Month Performance	N/A	7.12%	5.25%	4.54%
1 Year Performance	N/A	77.98%	33.29%	18.23%

NKGen Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NKGN NKGen Biotech	N/A	$0.06 flat	N/A	-80.0%	$7.84M	N/A	N/A	N/A	News Coverage
BGM BGM Group	0.7366 of 5 stars	$0.32 +1.9%	N/A	-96.8%	$30.82M	$26.85M	N/A	298	News Coverage Gap Up
NNVC NanoViricides	0.3813 of 5 stars	$1.34 +3.1%	N/A	-5.0%	$30.80M	N/A	N/A	20
LSTA Lisata Therapeutics	2.2797 of 5 stars	$3.36 -0.6%	$15.00 +346.4%	+26.1%	$30.78M	$170K	N/A	30
DARE Dare Bioscience	2.7478 of 5 stars	$2.09 +4.5%	$10.00 +378.5%	-12.9%	$29.96M	$1.03M	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NKGN) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NKGen Biotech (NKGN) Competitors

NKGN vs. BGM, NNVC, LSTA, DARE, and ATNM

How does NKGen Biotech compare to BGM Group?

Summary

How does NKGen Biotech compare to NanoViricides?

Summary

How does NKGen Biotech compare to Lisata Therapeutics?

Summary

How does NKGen Biotech compare to Dare Bioscience?

Summary

How does NKGen Biotech compare to Actinium Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NKGen Biotech (NKGN) Competitors

NKGN vs. BGM, NNVC, LSTA, DARE, and ATNM

How does NKGen Biotech compare to BGM Group?

Does the media prefer NKGN or BGM?

Is NKGN or BGM more profitable?

Do analysts rate NKGN or BGM?

Which has higher valuation and earnings, NKGN or BGM?

Which has more volatility and risk, NKGN or BGM?

Do insiders & institutionals have more ownership in NKGN or BGM?

Summary

How does NKGen Biotech compare to NanoViricides?

Which has more risk and volatility, NKGN or NNVC?

Do insiders & institutionals have more ownership in NKGN or NNVC?

Which has stronger earnings & valuation, NKGN or NNVC?

Do analysts prefer NKGN or NNVC?

Does the media prefer NKGN or NNVC?

Is NKGN or NNVC more profitable?

Summary

How does NKGen Biotech compare to Lisata Therapeutics?

Do insiders & institutionals believe in LSTA or NKGN?

Does the media favor LSTA or NKGN?

Which has more volatility and risk, LSTA or NKGN?

Is LSTA or NKGN more profitable?

Which has stronger valuation and earnings, LSTA or NKGN?

Do analysts recommend LSTA or NKGN?

Summary

How does NKGen Biotech compare to Dare Bioscience?

Does the media favor DARE or NKGN?

Which has more volatility and risk, DARE or NKGN?

Do institutionals & insiders have more ownership in DARE or NKGN?

Do analysts rate DARE or NKGN?

Which has better valuation & earnings, DARE or NKGN?

Is DARE or NKGN more profitable?

Summary

How does NKGen Biotech compare to Actinium Pharmaceuticals?

Do analysts prefer NKGN or ATNM?

Which has more volatility and risk, NKGN or ATNM?

Do insiders & institutionals believe in NKGN or ATNM?

Does the media prefer NKGN or ATNM?

Is NKGN or ATNM more profitable?

Which has better earnings & valuation, NKGN or ATNM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NKGN vs. The Competition

NKGen Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools